EyePoint, Inc. (EYPT)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$0.35-8.32%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put EYPT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Advance Phase 3 wet AMD program: Direct metric needs a verified mapping.
View ThesisRevenue is contracting — down about 93% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 4% on a typical day and fell roughly 98% in its worst 12-month stretch.
View RiskEyePoint’s thesis now rests on DURAVYU’s diabetic macular edema program after its wet AMD Phase 3 failure. Revenue fell 91% year over year in Q2 FY2026, and earnings missed. EYPT trades at 0.1× sales versus a 9.4× peer median. The desk says the price reflects less growth than its forecast. The model puts next-quarter miss probability near 71%. The wet AMD pillar failed, while DME data are expected in Q4 2027. Peer multiples imply a price well above where it trades; this read is provisional.
Trailing returns as of 2026-10-30. EYPT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering EYPT (as of Oct 2026).
Based on 7 Wall Street analysts offering 12-month price targets for EYPT in the last 4 months.
Continue this research
Compare EYPT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| EYPT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put EYPT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Prioritize DURAVYU Phase 3 development in DME
A reported trial miss threatens DURAVYU development; the price-target cut reflects, rather than independently changes, thesis risk.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $0.35
The last 12 months of price, then the range of analyst 12-month targets from today’s $0.35.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Threatens: Advance Phase 3 wet AMD program
Reported failure in a second pivotal eye-disease study threatens confidence in the wet AMD program.
Threatens: Advance Phase 3 wet AMD program
Reported pivotal wet AMD failure and 53% workforce reduction severely undermine the Phase 3 program.
Threatens: Advance Phase 3 wet AMD program
A Phase 3 miss and reported 53% workforce reduction signal severe program and organizational setbacks.
Threatens: Advance Phase 3 wet AMD program
Mixed trial data raises concerns about Phase 3 wet AMD program.
Threatens: Advance Phase 3 wet AMD program
Wet AMD setback impacts Phase 3 program progress.
Threatens: Advance Phase 3 wet AMD program
Primary endpoint miss impacts Phase 3 wet AMD program.
Threatens: Achieve full enrollment by Q3 2026 in Phase 3 DME trials
Trial miss impacts enrollment timeline for Phase 3 DME trials.
